Using the highly specific TAF assay for telomeric DNA damage, we did observe a trend for reduced TAFs in osteocytes with zoledronic acid treatment, but the differences did not reach statistical significance.
← all excerpts
<i>In vitro</i> and <i>in vivo</i> effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers.
1
—
—